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vention, supported by weekly telephone guidance by a 
counselor. The intervention included a self-help book that 
could be read at home. The primary outcome was the inci-
dence of relapse or recurrence and was assessed over the 
telephone by the Structured Clinical Interview for DSM-IV 
axis 1 disorders. Participants were observed for 12 months. 
Secondary outcomes were depressive symptoms, quality of 
life (EQ-5D and SF-12), comorbid psychopathology, and self-
efficacy. These secondary outcomes were assessed by digital 
questionnaires.  Results: In the S-PCT group, 44 participants 
(35.5%) experienced a relapse or recurrence, compared to 62 
participants (50.0%) in the TAU group (incidence rate ratio = 
0.71, 95% CI 0.52–0.97; risk difference = 14, 95% CI 2–24, 
number needed to treat = 7). Compared to the TAU group, 
the S-PCT group showed a significant reduction in depres-
sive symptoms over 12 months (mean difference –2.18; 95% 
CI –3.09 to –1.27) and a significant increase in quality of life 
(EQ-5D) (mean difference 0.04; 95% CI 0.004–0.08). S-PCT 
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 Abstract 
 Background: The burden and economic consequences of 
depression are high, mostly due to its recurrent nature. Due 
to current budget and time restraints, a preventive, low-
cost, accessible minimal intervention is much needed. In this 
study, we evaluated the effectiveness of a supported self-
help preventive cognitive therapy (S-PCT) added to treat-
ment as usual (TAU) in primary care, compared to TAU alone. 
 Methods: We conducted a randomized controlled trial 
among 248 patients with a history of depression, currently 
in full or partial remission or recovery. Participants were ran-
domized to TAU augmented with S-PCT ( n = 124) or TAU 
alone ( n = 124). S-PCT consisted of an 8-week self-help inter-
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had no effect on comorbid psychopathology, self-efficacy, 
and quality of life based on the SF-12.  Conclusions: A sup-
ported self-help preventive cognitive therapy, guided by a 
counselor in primary care, proved to be effective in reducing 
the burden of recurrent depression. 
 © 2017 The Author(s)
Published by S. Karger AG, Basel 
 Introduction 
 Major depressive disorder (MDD) is a prevalent men-
tal disorder and is associated with a high risk of relapse 
and recurrence  [1] . MDD is frequently associated with 
incomplete remission between episodes  [2, 3] and is con-
sidered to be among the most disabling illnesses  [4] , neg-
atively affecting many aspects of life  [5, 6] . Current guide-
lines recommend continuation of antidepressant medica-
tion (ADM) and/or psychological treatment, e.g., cognitive 
(behavioral) therapy (CT or CBT), to reduce the risk of 
relapse and recurrence  [7, 8] . The most commonly used 
strategy is a continuation of ADM  [9–12] . The recom-
mendations on ADM are under debate  [12] as the optimal 
duration of the continuation or maintenance phase has 
not been studied well enough  [9, 11] . Also, there is con-
flicting evidence about the effect of discontinuation of 
ADM on relapse or recurrence  [13] and, furthermore, re-
ported levels of ADM nonadherence have been consis-
tently high  [14] . In conclusion, proactive management 
based on the continuation of ADM alone may not be the 
most optimal strategy in preventing relapse or recur-
rence.
 Research demonstrates that psychological interven-
tions, specifically aimed at the prevention of relapse and 
recurrence in patients with a history of depression, of-
fered during the continuation or maintenance phase, are 
effective in reducing the risk of relapse and recurrence 
compared to treatment as usual (TAU), active control 
condition, and/or ADM  [15–19] . These interventions 
are mostly based on C(B)T  [20] , but add strategies such 
as modifying dysfunctional metacognitions in preven-
tive CT (PCT)  [21] and meditation in mindfulness-
based CT  [22] . Interpersonal psychotherapy links stress-
ful life events and insufficient social support to relapse 
and recurrence  [23] . The majority of these interventions 
is offered in secondary care, often relying on the inten-
sive use of therapist’s time, and, therefore, they are are 
costly. A minimally supported self-help intervention 
may help to overcome this problem. We considered the 
evidence base for CBT-based interventions to be the 
strongest  [17] and expected that a self-help intervention 
would be both low threshold and low cost, as was sug-
gested in an ante hoc health economic modeling study 
which was conducted before the trial-based evaluation. 
Finally, we expected that a minimally supported inter-
vention would keep dropout rates low. A recent trial by 
Gilbody et al.  [24] showed that the evidence for the ef-
fectiveness of standalone E-mental health interventions 
is limited. Therefore, the intervention included minimal 
support. Supported self-help has already proved as ef-
fective as face-to-face treatments in acutely depressed 
patients according to a meta-analysis of 21 studies, re-
porting an effect on symptoms of depression  [25] . The 
integration of supported self-help in primary care, sup-
ported by paraprofessionals  [25] , into current longitu-
dinal primary care systems, would fit best with the re-
current character of depression. The challenges in pro-
viding such service in primary care depend on the 
actual dynamics between the patients, health care pro-
fessionals, the intervention and the organization of care. 
Therefore, in this study, we conducted a randomized 
controlled trial to evaluate the effectiveness of a support-
ed self-help PCT (S-PCT) in primary care in patients 
with a history of depression, currently not meeting the 
criteria for depression.
 Methods 
 Design 
 We performed a pragmatic randomized controlled trial with 2 
parallel groups of participants comparing TAU augmented with 
S-PCT, with TAU alone. Participants were observed for 12 months. 
The design of this study is described in more detail elsewhere  [26] . 
The study was called the PARADE study (Prevention of Recurrent 
Depression). The study is registered in the Dutch Trial Register, 
www.trialregister.nl, under NTR3001.
 Ethics 
 The Medical Ethics Committee of the VU University Medical 
Center Amsterdam approved the study protocol (2011/285), and 
all participants provided written informed consent.
 Terminology 
 To describe the course of depression, we use the operational 
criteria of Frank et al.  [27] . According to these criteria, the course 
of depression is described as a series of disease stages in which a 
patient can move from a symptom-free stage to a stage character-
ized by some symptoms but not meeting the diagnostic criteria, to 
a stage with the full-blown disorder, after which the patient can go 
into remission. When a patient stays in remission for a minimum 
of 6 months, he or she is considered to be recovered. Subsequently, 
a relapse is defined as a depressive episode that occurs during re-
mission and before recovery, while a recurrence is defined as a 
depressive episode that occurs after recovery.
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 Participants 
 S-PCT was delivered in primary care, but recruitment took 
place through general practices in primary care and in mental 
health care services (secondary care) in the Netherlands. To be in-
cluded in the trial, participants had to (a) be 18 years or older, (b) 
be in full or partial remission (meaning the presence of residual 
symptoms) of recurrent MDD for at least 2 months, but no longer 
in recovery than 5 years according to the Structured Clinical Inter-
view for DSM-IV axis 1 disorders (SCID-1 3.0)  [28] , and (c) have 
experienced 2 or more previous episodes of MDD. The SCID-1 
interview was conducted over the telephone by trained researchers 
and psychologists. Telephone-administered SCIDs are valid and 
reliable compared to face-to-face administered SCIDs  [29] , which 
are considered the gold standard. Exclusion criteria were severe 
cognitive impairment, current or past mania, hypomania or psy-
chosis, current alcohol or drug abuse, or insufficient mastery of the 
Dutch language.
 Intervention 
 The intervention is an 8-week supported self-help and is a man-
ualized PCT-based bibliotherapy consisting of a printed self-help 
book with 8 modules and minimal guidance  [30] . It is based on an 
effective face-to-face PCT  [21] and mobile PCT  [31] . PCT is an 
adapted type of cognitive therapy for acute depression  [20] and aims 
to prevent relapse and recurrence in remitted patients with a his-
tory of depressive episodes. The intervention prevention program 
targets underlying cognitive vulnerability factors, such as dysfunc-
tional beliefs. Unlike CT for acutely depressed patients, S-PCT is not 
primarily directed toward modifying negative thoughts. Instead, it 
starts with the identification of negative thoughts and dysfunction-
al attitudes, aided by a self-report questionnaire with examples of 
attitudes and specific challenging techniques. The focus of the self-
help book is then directed on changing these attitudes by using dif-
ferent cognitive techniques such as identification of positive atti-
tudes. Moreover, practice in daily life with alternative attitudes is 
promoted. Part of the modules is keeping a diary of positive experi-
ences to enhance specific memories of positive experiences, instead 
of retaining overly general memories. Further specific relapse and 
recurrence prevention strategies are formulated in the last modules 
of the S-PCT resulting in a personal prevention plan. Like regular 
CT, PCT follows a fixed structure with agenda setting, review of 
homework, explanation of the rationale of each session, and the as-
signment of homework. Participants complete 1 module per week. 
Each module includes reading homework plus assignments, to be 
completed in approximately 60 min. In the current project, the 
counselor explained the rationale of PCT and coming weeks’ plan-
ning in a first contact (by phone or face to face), before the start of 
the intervention. Each week, the counselor contacted the partici-
pant by phone to evaluate progress and understanding. This call was 
strictly protocolled and was designed to last no longer than 15 min. 
The nature of the contact was solely to support the participant and 
not to engage in a therapeutic relationship actively.
 Counselors 
 Twenty-four counselors (primary care mental health nurses 
and psychologists) were trained to guide the intervention. The psy-
chologists were nonspecialized psychologists (i.e., without post-
doctoral training in clinical interventions). All counselors attend-
ed a 1-day training delivered by experienced clinical psychologists, 
who developed the intervention and therefore had an intimate 
knowledge of S-PCT. Before the start of the trial, the trainers eval-
uated the competence of the counselors by giving feedback on au-
diotaped telephone contacts with 2 pilot patients for each coun-
selor during a 1-day supervision session. During the trial, counsel-
ors could contact the trainers at any time for additional questions 
and feedback. To assess adherence, each week, the counselor com-
pleted a checklist with 4 items: (1) the number of that week’s mod-
ule (1–8), (2) the compliance of the participants in reading the 
literature of that week (yes/no plus reason), (3) the compliance of 
the participants in doing the assignments (yes/no plus reason), and 
(4) the time spent on the call (min).
 Treatment as Usual 
 There were no restrictions on the type of TAU. Service provid-
ers who did not know their patients were enrolled in a study and 
patients were asked not to tell their service providers about their 
enrollment.
 Current TAU guidelines recommend encouraging a person 
who has benefited from taking ADM, to continue ADM for at least 
6 months after remission of an episode of depression. On psycho-
logical interventions, guidelines recommend offering CBT to per-
sons with a significant history of depression plus residual symp-
toms and mindfulness-based CT to patients with a history of at 
least 3 episodes of depression  [7, 8] . TAU was recorded using the 
Trimbos and iMTA self-report questionnaire for Costs associated 
with Psychiatric Illnesses  [32] .
 Treatment Allocation 
 Once participants had provided informed consent, they re-
ceived the SCID interview to assess eligibility criteria. When par-
ticipants were eligible, randomization was conducted by an inde-
pendent statistician using computer-generated random numbers 
in blocks of size 2. Participants were randomized on the order in 
which their baseline SCID interview was conducted by the re-
searchers. Randomization was stratified by the number of previous 
depressive episodes (2–3 vs.  ≥ 4 episodes) because the number of 
previous episodes is associated with relapse and recurrence  [33] . 
Randomization was concealed from the assessors who conducted 
interviews during the observation period, as they were not in-
formed about the participants’ randomization status, and partici-
pants were requested not to disclose randomization status to the 
assessors.
 Blinding 
 Interviewers were blind to the randomization status of the par-
ticipants during all measurements. Due to the nature of the inter-
vention, it was not possible to blind the participants. At the start 
of each interview, participants were asked not to reveal their ran-
domization status to the interviewers.
 Outcome Measures 
 Primary Outcome 
 The primary outcome was the incidence rate of relapse or re-
currence of depression. Participants were observed for 12 months 
beginning with the start of the intervention which took place with-
in 2 weeks after randomization. To reduce recall bias, telephone 
SCID interviews were conducted over 6 months, at 6 and 12 
months and combined into a single outcome (0 = no relapse or 
recurrence, 1 = relapse or recurrence). The incidence rate ratio 
(IRR) was calculated by comparing the incidence rates of new ep-
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isodes in both conditions. An IRR <1 implies a better risk reduc-
tion in the intervention group relative to the control group; the 
intervention is then deemed successful. IRR = 1 and IRR >1 imply 
no effect or an adverse effect, respectively. In case participants 
proved depressive according to the telephone SCID interview, they 
were advised to contact their primary care physician or mental 
health caregiver. In the case of suicide thoughts or beliefs, we con-
tacted the general practitioner immediately which was signed for 
in the informed consent.
 Secondary Outcomes 
 Secondary outcomes were assessed online at baseline and at 6 
and 12 months (depressive symptomatology, health-related qual-
ity of life) or at 9 and 12 months (comorbid psychopathology, self-
efficacy).
 Depressive symptoms were assessed using the Dutch translation 
of the Quick Inventory of Depressive Symptomatology-Self Report 
(QIDS-sr)  [34] .  This self-report questionnaire consists of 16 symp-
tom items to be answered on a 4-point Likert scale. A score of 0–5 
is categorized as no depressive symptoms, 6–10 as mild, 11–15 as 
moderate, 16–20 as severe, and 20–27 as very severe depressive 
symptoms.
 Health-related quality of life was examined using the Dutch 
translations of the 12-Item Short-Form Health Survey (SF-12)  [35] 
and the European Quality of Life Five-Dimensions (3-level) Health 
Status Questionnaire (EQ-5D)  [36] . The SF-12 is a measure of 
health-related functional status  [37] and yields 2 summary mea-
sures of physical and mental health. It is the most commonly used 
health measure and, therefore, outcomes can be easily compared 
to other studies using the SF-12. The EQ-5D measures health-re-
lated quality of life on 5 dimensions (mobility, self-care, usual ac-
tivities, pain/discomfort, and anxiety and depression), combined 
into 1 outcome. Each dimension is rated at 3 levels corresponding 
to whether a respondent has no problems, moderate or extreme 
problems. The value of each of the 243 health states is preference 
weighted using valuations from the Dutch population  [38] . Be-
sides the SF-12, we used the EQ-5D because it is the most com-
monly used health measure in a cost-effectiveness analysis, which 
we plan to report.
 Comorbid symptoms  were measured with the Four-Dimen-
sional Symptom Questionnaire  [39] , which is a self-rating ques-
tionnaire that comprises 50 items distributed over 4 scales (dis-
tress, depression, anxiety, and somatization).
 Perceived  self-efficacy was assessed with the General Self-Effi-
cacy Scale  [40] , which consists of 10 items, scored 1–4. Especially 
in the self-help condition, self-efficacy might change in the course 
of the intervention and during the observation period.
 Sample Size 
 We combined findings from previous research  [16, 41] and as-
sumed a mean relapse or recurrence rate of 40% during the obser-
vation period versus 60% in the controls. To detect this 20% risk 
reduction in a 2-sided test at α = 0.05 and a power of 1 – β = 0.80, 
107 participants in each condition were required. Compensating 
for loss to follow-up of 10% over the whole 12-month observation 
period required at least (107/0.90 =) 119 participants at baseline in 
each trial arm. Our own experience with randomization of patients 
at general practice level  [42, 43] indicates that clustering of patients 
within practices has no impact on the power of the trial. Therefore, 
we did not take clustering effects into account.
 Statistical Analyses 
 We investigated whether baseline characteristics differed be-
tween conditions. In addition, we compared the baseline charac-
teristics of dropouts and those who completed all measurements 
during the 12-month observation period by performing logistic 
regression analysis. Data were primarily analyzed on the basis of 
the intention-to-treat (ITT) principle. Missing values on outcome 
measures were imputed using multiple (10-fold) imputation by 
chained equations  [44] . The analyses were performed in each of 
the 10 data sets, and the results of the analyses were pooled using 
the Rubin rules  [45] .
 To compare risk on relapse or recurrence in both conditions, 
we performed a Poisson regression analysis of the incidence of re-
lapse or recurrence on the treatment condition. In this manner, we 
obtained an IRR. Because the use of Poisson regression tends to 
provide conservative results  [46, 47] and overestimates error  [47] , 
we used the Hubert-White sandwich estimator as implemented in 
STATA  [48] . Results were adjusted for baseline (residual) depres-
sive symptoms (QIDS-sr). Previous trials indicated that depres-
sion status is associated with relapse/recurrence, and therefore we 
adjusted to improve our estimates  [49, 50] .
 Estimates of the intervention effects on the secondary outcome 
measures (all continuous) were obtained over 12 months from 
linear mixed models. Randomization status,  R,  time of measure-
ments,  T , and randomization-by-time interaction  (R × T) were 
included as fixed effects in the models. The participants’ identifi-
cation was included as random term because in the long data set 
the same participant could have contributed to the data set at 
some or all time points. We assessed the overall effect of the inter-
vention by testing the interaction between randomization and 
time of measurement that was associated with outcome. Means 
were adjusted for baseline level of the outcome. In linear mixed 
models, imputation of missing data is not necessary. The results 
of the ITT analysis were compared with the results of the per-
protocol analysis, including those participants who completed at 
least 80% of the intervention (5 modules). All analyses were per-
formed with STATA (version 12). Statistical significance was test-
ed 2-tailed.
 Results 
 Recruitment 
 Details of enrollment are shown in  Figure 1 . Recruit-
ment took place between September 2012 and April 2014. 
Medical records of 22 family practices and 4 specialized 
mental health care institutions were screened for eligible 
patients. This led to the selection of 5,489 patients, who 
received a short information letter. Finally, 248 patients 
met all inclusion criteria and signed an informed consent. 
They were randomly allocated to the S-PCT group (124) 
or to the TAU group (124). In primary care, 3,517 invita-
tion letters led to 129 participants (3.7%), and in second-
ary care 1,971 letters led to 109 (5.6%). Primary care pa-
tients had a mean QIDS-sr score of 9.13 (SD = 4.58), and 
secondary care patients scored 9.31 (SD = 5.24).
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Excluded (n = 564)
• Declined to practicipate  (n = 256)
• Not eligible according to 
  initial screening  (n = 308)
• Completed questionnaires  (n = 109/124)
• Completed interview (n = 109/124)
• Completed questionnaires  (n = 107/124)
• Completed interview (n = 111/124)
Analyzed intention to treat  (n = 124)
Analyzed per protocol (n = 101)
Analyzed complete follow-up (n = 95)
Analyzed intention to treat  (n = 124)
Analyzed per protocol (n = 124)
Analyzed complete follow-up (n = 93)
Randomized (n = 248)
Assessed for eligibility by
SCID-1 interview (n = 284)
Patients invited by letter
(n = 5,489)
Patients replied to initial screening
questionnaire (n = 848)
Allocated to PCT + TAU  (n = 124)
• Received PCT + TAU  (n = 117)
• Did not receive PCT + TAU (n = 7)
Reasons:
Too depressed (n = 2)
Takes too much time  (n = 1)
Therapy is too emotional  (n = 2)
Therapist advised to cancel (n = 1)
Unknown (n = 1)
Excluded  (n = 36)
• Declined to participate  (n = 2)
• Not meeting inclusion criteria  (n = 34)
Current/chronic depression (n = 9)
Last episode >5 years  (n = 8)
No recurrent depression  (n = 9)
    No or one depression (n = 4)
    Burnout only (n = 3)
    Anxiety only  (n = 2)
Current substance abuse  (n = 1)
Bipolar disorder (n = 4)
Psychosis (n = 3)
• Allocated to TAU  (n = 124)
• Received TAU (n = 124)
Withdrew in TAU group 
immediately after start of study  (n = 6)
• Completed PCT + TAU  (n = 101/117)
• Discounted intervention (n = 16)
Reasons:
Takes too much time (n = 4)
Therapy is too emotional  (n = 2)
Too much therapy already (n = 1)
Lack of motivation (n = 2)
Too difficult  (n = 3)
No restrictive rule (n = 2)
Other (n = 2)
• Completed 12-month follow-up  (n = 95/124)
– Completed questionnaires (n = 98/124)
– Completed interviews (n = 104/124)
• Lost to follow-up (n = 29)
Reasons:
Unknown (n = 6)
Logistical reason  (n = 3)
Lack of motivation (n = 4)
Stopped with intervention also (n = 5)
Too stressful due to 
      personal circumstances   (n = 1)
Lack of time/no priority (n = 2)
Acute depression? (n = 2)
Other (n = 3)
• Completed 12-month follow-up  (n = 93/124)
– Completed questionnaires (n = 95/124)
– Completed interviews (n = 106/124)
• Lost to follow-up (n = 31/124)
Reasons:
Unknown (n = 8)
Logistical reason  (n = 4)
Too stressful to fill 
      in questionnaires   (n = 2)
Acute depression? (n = 4)
Too stressful due to 
      personal circumstances   (n = 4)
Unable to contact (n = 4)
Lack of motivation (n = 3)
Other (n = 2)
Informed consent
Analysis
Allocation
Enrollment
12-month follow-up
6-months follow-up
 Fig. 1. Participant flow diagram. 
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 Baseline Characteristics 
 In  Table  1 , baseline sociodemographic and clinical 
characteristics of the ITT group are presented. No rele-
vant baseline imbalances were found. At baseline, all par-
ticipants were in (partial) remission or recovery of recur-
rent MDD and experienced mild depressive symptoms 
(mean QIDS-sr = 9.3, SD = 4.9). The intervention group 
had a mean QIDS-sr score of 9.6 (SD = 4.8) and the con-
trols one of 8.9 (SD = 5.0), indicating moderate residual 
symptoms.
 Numbers Analyzed 
 Complete data for the 12-month observation period 
were collected from 95/124 participants (77%) in the in-
tervention group and 93/124 participants (75%) in the 
control group, which was not statistically different 
[χ 2 (247) = 0.088]. Loss to follow-up was significantly as-
sociated with more fatigue at baseline [difference in 
mean = 0.602, 95% CI 0.115–1.089,  t (235) = 2.437,  p = 
0.016].
 Primary Outcome 
 Incidence of Relapse or Recurrence of Depression 
 Twelve months after randomization, a new relapse or 
recurrence of depression had occurred in 44 (35.5%) par-
ticipants in the intervention group and 62 (50.0%) par-
ticipants in the control group ( Table  2 ). The IRR was 
therefore 35.5/50.0 = 0.71 [95% CI 0.52–0.97,  t (234.4) = 
–2.16,  p = 0.032]. The risk difference between the TAU 
group and the S-PCT group was 50.0–35.5 = 14.5% [95% 
CI 2–24,  t (167.7) = –2.25,  p = 0.025] which corresponds 
to a number needed to treat of 7 ( Table 3 ).
 Table 1.  Baseline demographic and descriptive characteristics of the study population according to randomized 
group
Characteristics S-PCT
(n = 124)
TAU
(n = 124)
All participants
(n = 248)
Age, years 48.6 ± 11.9 48.8 ± 11.4 48.7 ± 11.7
Females, n (%) 89 (71.8) 84 (67.7) 173 (69.8)
Previous episodes, %
2 or 3 53.2 49.9 51.6
4 or more 46.8 50.1 48.4
Marital status, %
Partner 64.9 64.9 64.9
Education, %
High educationa 42.7 35.5 39.1
Age at onset, years 28.2 ± 11.4 27.5 ± 12.3 27.8 ± 11.9
Depressive symptoms (QIDS-sr) 9.6 ± 4.8 8.9 ± 5.0 9.3 ± 4.9
Quality of life
Mental health (SF-12) 53.6 ± 12.2 53.5 ± 11.6 53.5 ± 11.9
Physical health (SF-12) 59.4 ± 11.4 57.6 ± 11.7 58.5 ± 11.6
EQ-5D 0.77 ± 0.21 0.78 ± 0.20 0.77 ± 0.2
Comorbid psychopathology (4-DSQ)
Anxiety 3.2 ± 3.9 3.2 ± 4.3 3.2 ± 4.1
Distress 13.0 ± 7.6 12.7 ± 8.0 12.8 ± 7.8
Somatization 8.1 ± 5.5 8.9 ± 5.7 8.5 ± 5.6
Pain (MPQ) 2.5 ± 3.6 3.2 ± 4.2 2.8 ± 3.9
Fatigue (FSS) 3.8 ± 1.5 3.9 ± 1.6 3.8 ± 1.6
Self-efficacy (GSES) 28.6 ± 5.9 28.3 ± 6.2 28.4 ± 6.0
ADM use past 3 months, % 51.8 56.7 54.2
 Results are expressed as means ± SD unless indicated otherwise. TAU, treatment as usual; SD, standard de-
viation; ADM, antidepressant medication; SF-12, 12-Item Short-Form Health Survey; MPQ, MacGill Pain Ques-
tionnaire; FSS, Fatigue Severity Scale; GSES, General Self-Efficacy Scale; EQ-5D, European Quality of Life Five-
Dimensions Health Status Questionnaire; QIDS-sr, Quick Inventory of Depressive Symptoms Self-Report; 
4-DSQ, Four-Dimensional Symptom Questionnaire. Standard deviations for multiply imputed data were com-
puted from the standard errors: SD = sqrt(_b[var2] – _b[var] × _b[var]). a High education is defined as bachelor’s 
or master’s degree.
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 Secondary Outcomes 
 Depressive symptom scores in the intervention group 
decreased significantly compared to TAU over 12 
months with 2.18 QIDS-sr points (95% CI –3.09 to 
–1.27,  Z = –4.70,  p < 0.001). This longitudinal between-
group mean difference (with an SD of 7.3) translates into 
a clinically small standardized effect size of  d = 0.30  [51] . 
Quality of life improved significantly with a between-
group mean difference of 0.04 EQ-5D points (95% CI 
0.004–0.08,  Z = 2.18,  p = 0.029). No significant effects 
were found on any of the other secondary outcomes
( Table 2 ).
 Table 2.  Descriptive unadjusted statistics at baseline, 6 and 12 months: ITT analysis and per-protocol (PP) anal-
ysis
ITT analysis  PP analysis
S-PCT 
(n = 124)
TAU
(n = 124)
S-P CT 
(n = 101)
TAU
(n = 124)
Primary outcome
Relapse or recurrence after 12 months 44/124 (35.5) 62/124 (50.0) 35/101 (34.7) 62/124 (50)
Secondary outcomes
Depressive symptoms (QIDS-sr)
Baseline 9.6 ± 4.8 8.9 ± 5.0 10.1 ± 4.8 8.9 ± 5.0
6 months 6.3 ± 4.3 8.7 ± 4.9 6.3 ± 4.3 8.7 ± 4.9
12 months 7.2 ± 4.9 7.7 ± 5.3 7.3 ± 4.8 7.7 ± 5.3
Functional impairment (SF-12, mental)
Baseline 53.6 ± 12.2 53.5 ± 11.6 53.5 ± 12.1 53.5 ± 11.6
6 months 53.3 ± 10.7 51.7 ± 11.8 53.1 ± 10.6 51.7 ± 11.8
12 months 53.4 ± 10.4 54.4 ± 12.2 53.2 ± 10.6 54.4 ± 12.2
Functional impairment (SF-12, physical)
Baseline 59.4 ± 11.4 57.6 ± 11.7 59.3 ± 11.6 57.6 ± 11.7
6 months 58.7 ± 10.8 56.8 ± 11.5 58.9 ± 10.4 56.8 ± 11.5
12 months 60.5 ± 11.5 58.8 ± 12.6 60.3 ± 11.6 58.8 ± 12.6
Health-related quality of life (EQ-5D)
Baseline 0.77 ± 0.21 0.78 ± 0.20 0.74 ± 0.22 0.78 ± 0.20
6 months 0.81 ± 0.19 0.77 ± 0.20 0.81 ± 0.19 0.77 ± 0.20
12 months 0.80 ± 0.19 0.78 ± 0.24 0.79 ± 0.19 0.78 ± 0.24
Anxiety (4-DSQ)
Baseline 3.2 ± 3.9 3.2 ± 4.3 3.5 ± 4.0 3.2 ± 4.3
9 months 3.0 ± 3.7 2.6 ± 4.1 3.1 ± 3.7 2.6 ± 4.1
12 months 2.8 ± 3.7 2.9 ± 4.2 2.9 ± 3.7 2.9 ± 4.2
Distress (4-DSQ)
Baseline 13.0 ± 7.6 12.7 ± 8.0 13.7 ± 7.7 12.7 ± 8.0
9 months 12.3 ± 8.1 11.5 ± 8.8 12.4 ± 8.0 11.5 ± 8.8
12 months 11.9 ± 8.8 11.6 ± 8.7 12.1 ± 8.8 11.6 ± 8.7
Somatization (4-DSQ)
Baseline 8.1 ± 5.5 8.9 ± 5.7 8.4 ± 5.8 8.9 ± 5.7
9 months 8.2 ± 5.8 8.4 ± 6.0 8.4 ± 5.9 8.4 ± 6.0
12 months 7.6 ± 5.4 7.6 ± 5.4 7.8 ± 5.4 7.6 ± 5.4
Self-efficacy (GSES)
Baseline 28.6 ± 5.9 28.3 ± 6.2 28.3 ± 6.2 28.3 ± 6.2
9 months 28.8 ± 6.8 29.3 ± 6.2 28.8 ± 6.7 29.3 ± 6.2
12 months 28.6 ± 7.1 28.8 ± 7.0 28.5 ± 7.0 28.8 ± 7.0
 Primary outcomes are expressed as n (%) and secondary outcomes as means ± SD. EQ-5D, European Qual-
ity of Life Five-Dimensional Health Status Questionnaire; ITT, intention-to-treat; QIDS-sr, Quick Inventory of 
Depressive Symptoms Self-Report; GSES, General Self-Efficacy Scale; 4-DSQ, Four-Dimensional Symptom 
Questionnaire; SF-12, 12-Item Short-Form Health Survey; TAU, treatment as usual; S-PCT, self-help preventive 
cognitive therapy; SD, standard deviation.
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 The Supported Self-Help Intervention 
 Seven participants did not start the supported self-help 
intervention (7/124 = 6%). Two participants dropped out 
after the first contact (2%), and 5 participants dropped 
out after the first S-PCT meeting (4%). Reasons for drop-
out are shown in  Figure 1 . From the 117 participants who 
started the intervention, 16 (18.5%) dropped out during 
the intervention, all before week 6 of the intervention. In 
total, 101 participants (81%) completed at least 5 modules 
(80%), and were labeled as “completers.” At baseline, 
completers experienced more depressive symptoms 
[mean difference = 2.22, 95% CI 0.010–4.35,  t (236) = 2.06, 
 p = 0.04], more distress [mean difference = 3.46, 95% CI 
0.02–6.90,  t (235) = 1.98,  p = 0.049] and a lower quality of 
life (EQ5D) [mean difference = –0.11, 95% CI 0.02–0.20, 
 t (236) = –2.52,  p = 0.012] than noncompleters.
 Participants were supported by a primary care mental 
health nurse (31.5%) or by a nonspecialized psychologist 
(68.5%). The first contact was organized face to face 
(40.3%) or by telephone (59.1%). The mean amount of 
time spent per phone call per participant by the counsel-
or was 13.8 min (SD = 5.42), totaling a mean of 110.2 min 
of attention per participant per treatment. Adjusting for 
the type of counselor, the type of first contact or the mean 
length of time spent per phone call per participant did not 
influence the results on effectiveness. No adverse events 
were observed.
 According to the checklist of the counselors, in 6% of 
all contacts, the participant had not read the literature be-
longing to that week’s module. Reasons for not reading 
the literature were (more than 1 reason per participant 
was possible): lack of time (19), too difficult (10), practical 
considerations (7), too depressed (6), did not feel like it 
(1), other (3). In 11% of all contacts, the participants de-
clared they did not complete the assignments for that 
week’s module. Reasons for not doing assignments were: 
lack of time (28), too difficult (21), too depressed (11), 
practical considerations (11), did not feel like it (5), phys-
ical illness (5), intervention does not meet expectations 
(2), other (2).
 Treatment as Usual 
 At the end of the 12-month observation period, the 
percentage of participants in the S-PCT group and TAU 
group who received ADM at any moment during the past 
3 months was 47% for both groups [χ 2 (1) = 0.0001,  p = 
0.994]. Compared to baseline, relatively more partici-
pants in the TAU group stopped using ADM than in the 
 Table 3.  Testing the between-group differences over 12 months using Poisson regression and linear mixed modeling adjusting for the 
baseline values of the dependent variable (ITT analysis and per-protocol, PP, analysis)
Primary outcome ITT analysis (S-PCT: n = 124; TAU: n = 124) PP analysis (S-PCT: n = 101; TAU: n =  124)
IRRa (95% CI) RDb (95% CI) NNT IR Rc (95% CI) RDd (95% CI) NNT
Relapse or recurrence 0.71 (0.52 to 0.97) 14 (2 to 24) 7 0.68 (0.50 to 0.93) 15 (4 to 25) 7
Secondary outcomes Mean group 
difference1 (95% CI) 
Z value p Mean group 
difference1 (95% CI)
Z value p
Depressive symptoms (QIDS-sr) –2.18 (–3.09 to –1.27) –4.70 <0.001 –2.31 (–3.26 to –1.37) –4.81 <0.001
Health-related quality of life (SF-12, mental) 0.67 (–1.33 to 2.67) 0.65 0.513 0.44 (–1.62 to 2.50) 0.42 0.675
Health-related quality of life (SF-12, physical) 1.05 (–0.81 to 2.91) 1.10 0.270 0.89 (–1.01 to 2.80) 0.92 0.359
Health-related quality of life (EQ-5D) 0.04 (0.004 to 0.08) 2.18 0.029 0.04 (0.003 to 0.81) 2.10 0.036
Anxiety (4-DSQ) –0.05 (–0.68 to 0.59) –0.14 0.887 –0.05 (–0.71 to 0.60) –0.16 0.872
Distress (4-DSQ) –0.21 (–1.81 to 1.39) –0.26 0.798 –0.25 (–1.90 to 1.41) –0.29 0.769
Somatization (4-DSQ) 0.38 (–0.64 to 1.39) 0.73 0.464 0.42 (–0.63 to 1.48) 0.79 0.432
Self-efficacy (GSES) –0.68 (–1.91 to 0.55) –1.08 0.280 –0.57 (–1.81 to 0.67) –0.91 0.36
 QIDS-sr, Quick Inventory of Depressive Symptoms Self-Report; CI, confidence Interval; GSES, General Self-Efficacy Scale; 4-DSQ, Four-Dimensional 
Symptom Questionnaire; EQ-5D, European Quality of Life Five-Dimensional Health Status Questionnaire; SF-12, 12-Item Short-Form Health Survey; IRR, 
incidence rate ratio; ITT, intention-to-treat; NNT, number needed to treat; RD, risk difference; TAU, treatment as usual; S-PCT, supported self-help preven-
tive cognitive therapy. 
ITT: a p = 0.032; an IRR <1 means that over 12 months more patients in the TAU group recurred compared to the S-PCT group; scores were adjusted 
for depressive symptoms (QIDS-sr) at baseline; b p = 0.025; RD is the percentage risk difference in relapse and recurrence rate between S-PCT and TAU over 
the 12-month observation period. PP: c p = 0.017; scores were adjusted for depressive symptoms (QIDS-sr) at baseline; d p = 0.011; RD is the percentage risk 
difference in relapse and recurrence rate between S-PCT and TAU over the 12-month observation period. 1 Scores were adjusted for baseline level of the 
outcome and estimated with linear mixed modeling.
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S-PCT group during the observation period, but this dif-
ference was not significant ( p = 0.742). At the end of the 
12-month observation period, 43% of the participants in 
the S-PCT group received additional counseling from a 
psychiatrist/psychologist/psychotherapist versus 40% of 
the participants in the TAU group [χ 2 (1) = 0.172,  p = 
0.678].
 Per-Protocol Analysis 
 The per-protocol analysis included only those partici-
pants who completed at least 80% (5 modules) of the in-
tervention (81%; 101/124 participants). The results were 
roughly comparable to the results of the ITT analysis. The 
difference in incidence rate of relapse or recurrence be-
tween the S-PCT group and the TAU group was more 
pronounced than in the ITT analysis [IRR = 0.68, 95% CI 
0.50–0.93,  t (370.3) = –2.39,  p = 0.017; risk difference = 
15%, 95% CI 4–25, number needed to treat = 7] ( Table 3 ). 
Similar to the ITT analysis, both the depressive symptoms 
score and quality of life score (EQ5D) changed signifi-
cantly over 12 months in the intervention group com-
pared to the TAU group (–2.31 QIDS-sr points, 95% CI 
–3.26 to –1.37,  Z = –5.87,  p  < 0.001; 0.04 points, 95% CI 
0.003–0.81,  Z = 2.10,  p = 0.036, respectively).
 Discussion 
 The patient group in our trial was clearly vulnerable as 
no less than 50% of the participants who received usual 
care experienced a relapse or recurrence of depression 
within 12 months. In the intervention group this percent-
age was reduced, but still, one third of the patients in the 
S-PCT group relapsed, which underlines the public health 
significance of ongoing development of proactive strate-
gies. The IRR of 0.71 that we found was somewhat higher 
(i.e., the intervention may have been less effective) than 
the IRR we found in our meta-analysis (0.64) comparing 
psychological interventions to usual care  [17] . Partici-
pants in our trial experienced a higher level of residual 
symptoms than participants in the studies that were in-
cluded in the meta-analysis, and therefore, the a priori 
chance of relapse or recurrence might have been higher 
in our trial. An average health gain of 0.04 quality-adjust-
ed life years in the intervention group is perhaps only just 
noticeable by the participants as a subjectively felt im-
provement of the quality of their lives  [52] .
 The reach of possible eligible patients may have worked 
better in secondary than in primary care because of the 
higher motivation and because diagnoses are more ex-
plicit. Relapse prevention offered shortly after the depres-
sion has remitted is most successful because the motiva-
tion to participate might be optimal at that time  [17] .
 Loss to follow-up was around 24% in both arms in-
stead of an assumed loss to follow-up of 10%. Perhaps, a 
self-help approach is too “light-weighted,” and the same 
characteristics that lead to a patient’s vulnerability to de-
pression (feelings of worthlessness, loss of interest, etc.) 
may cause an earlier dropout in this type of intervention.
 Finally, results of the ITT analysis and the per-protocol 
analysis appeared quite similar. These results might im-
ply that receiving the suggested number of sessions has a 
limited impact on the final results.
 A strength of our study is that our operationalization 
of depression and relapse or recurrence was based on a 
structured clinical interview (SCID-1). A further strength 
is that our participants achieved remission and/or recov-
ery on antidepressants, other psychotherapies, psychiat-
ric help, counseling, or no treatment at all, as typically 
present in clinical practice. Moreover, there were no re-
strictions in using medication at entry to the study. There-
fore, this study was designed to maximize external valid-
ity, which suggests good generalizability of the findings. 
Third, very few prevention studies have been performed 
at the interface of primary and secondary care.
 Our study also has limitations. First, though the nature 
of the contact between the counselor and the participant 
was solely to support the participant and not to actively 
engage in a therapeutic relationship, still the interperson-
al relationship may have served as an effective element of 
therapy in and of itself. Secondly, we did not adjust for the 
fact that some forms of TAU could in and by themselves 
be more effective in reducing relapses and recurrences 
than others, which may have partially caused superiority 
of S-PCT. Yet, over 12 months the use of antidepressant 
medication, which is the first-step treatment in guidelines 
for recurrent depression, was not associated with treat-
ment condition in the study. Thirdly, survival analyses, 
with time to recurrence as the outcome measure, would 
have allowed better comparisons to the literature, would 
have opened the exploration of the distribution of the 
hazards over time and given us an idea how long it takes 
for the intervention to work. Fourth, we did not adjust for 
risk factors for developing depression such as chronic 
medical conditions and must assume that randomization 
has led to a balanced distribution of such factors across 
the conditions. Fifth, the intervention in our trial was of-
fered at a random moment during remission or recovery: 
some participants had been recovered for up to 5 years 
(and thus were at low risk for recurrence) while others 
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were in remission or partial remission for only 2 months 
(and thus were at high risk for relapse). This clinical het-
erogeneity might have impacted overall results.
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